We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
New Marijuana Stocks? & Earnings from ORCL and FDX | Free Lunch
Read MoreHide Full Article
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney touches on the trade war’s latest tariff threats and a key FDA approval for Teva Pharmaceuticals. He also highlights two surprising companies which might have a chance to profit from the marijuana boom.
Later, Ryan previews Oracle and FedEx’s earnings reports.
Free Lunch is the newest show from Zacks Investment Research. It is streamed live, four times per week, and features breaking news and analysis from Zacks strategists. Free Lunch is available on YouTube, Facebook Live, Twitter, Ustream, and more.
Stocks were down in morning trading Monday as Wall Street braced for another escalation in the ongoing trade war between the U.S. and China. Reports over the weekend indicated that President Donald Trump will opt for a new batch of 10% charges on Chinese goods, and although that is below the threatened 25% level, investors were still frustrated.
Elsewhere, the struggling Teva Pharmaceuticals (TEVA - Free Report) received FDA approval on a new migraine therapy. Nearly 12% of the U.S. population suffers from migraines, so Teva’s new treatment—which will be administered via monthly or quarterly injections—could be huge for the company. Teva has struggled recently as its stock has tumbled over the past three years.
Investors on Monday were also continuing to discuss ways to gain exposure to the booming marijuana industry, with reports and analyst notes highlighting two potential new options: Coca-Cola (KO - Free Report) and Shopify (SHOP - Free Report) .
Indeed, Coca-Cola is reportedly engaged in talks with a cannabis producer to develop drinks infused with CBD, a non-psychoactive chemical found in marijuana which is used to treat inflammation and anxiety. Meanwhile, analysts pointed out in a bullish note that Shopify has become the go-to online platform for Canadian pot companies.
Make sure to check out the first half of the episode, where Ryan recaps all of these news stories! But also stick around for the second half of the show, as the host digs into upcoming earnings reports from the likes of Oracle (ORCL - Free Report) and FedEx (FDX - Free Report) .
Oracle shares are up just 5% on the year as investors continue to worry that the company is losing market share to key competitors, but the software and cloud computing giant is still expected to see a nice 10% uptick in earnings this quarter.
Meanwhile, FedEx has struggled to generate momentum amid market-wide headwinds but has still benefitted from healthy consumer economy. The shipping behemoth has also been focusing on strategic initiatives and is projected to notch earnings growth of more than 50% in the soon-to-be-reported period.
Don’t miss this period of the show if you are interested in either of these reports this afternoon! Finally, make sure to check out Free Lunch’s Q&A session at the end of the episode as Ryan fields questions about Greensky , Twitter , and Costco (COST - Free Report) .
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
Image: Bigstock
New Marijuana Stocks? & Earnings from ORCL and FDX | Free Lunch
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney touches on the trade war’s latest tariff threats and a key FDA approval for Teva Pharmaceuticals. He also highlights two surprising companies which might have a chance to profit from the marijuana boom.
Later, Ryan previews Oracle and FedEx’s earnings reports.
Want more video content from Zacks? Subscribe to Zacks Investment News now!
Free Lunch is the newest show from Zacks Investment Research. It is streamed live, four times per week, and features breaking news and analysis from Zacks strategists. Free Lunch is available on YouTube, Facebook Live, Twitter, Ustream, and more.
Stocks were down in morning trading Monday as Wall Street braced for another escalation in the ongoing trade war between the U.S. and China. Reports over the weekend indicated that President Donald Trump will opt for a new batch of 10% charges on Chinese goods, and although that is below the threatened 25% level, investors were still frustrated.
Elsewhere, the struggling Teva Pharmaceuticals (TEVA - Free Report) received FDA approval on a new migraine therapy. Nearly 12% of the U.S. population suffers from migraines, so Teva’s new treatment—which will be administered via monthly or quarterly injections—could be huge for the company. Teva has struggled recently as its stock has tumbled over the past three years.
Investors on Monday were also continuing to discuss ways to gain exposure to the booming marijuana industry, with reports and analyst notes highlighting two potential new options: Coca-Cola (KO - Free Report) and Shopify (SHOP - Free Report) .
Indeed, Coca-Cola is reportedly engaged in talks with a cannabis producer to develop drinks infused with CBD, a non-psychoactive chemical found in marijuana which is used to treat inflammation and anxiety. Meanwhile, analysts pointed out in a bullish note that Shopify has become the go-to online platform for Canadian pot companies.
Make sure to check out the first half of the episode, where Ryan recaps all of these news stories! But also stick around for the second half of the show, as the host digs into upcoming earnings reports from the likes of Oracle (ORCL - Free Report) and FedEx (FDX - Free Report) .
Oracle shares are up just 5% on the year as investors continue to worry that the company is losing market share to key competitors, but the software and cloud computing giant is still expected to see a nice 10% uptick in earnings this quarter.
Meanwhile, FedEx has struggled to generate momentum amid market-wide headwinds but has still benefitted from healthy consumer economy. The shipping behemoth has also been focusing on strategic initiatives and is projected to notch earnings growth of more than 50% in the soon-to-be-reported period.
Don’t miss this period of the show if you are interested in either of these reports this afternoon! Finally, make sure to check out Free Lunch’s Q&A session at the end of the episode as Ryan fields questions about Greensky , Twitter , and Costco (COST - Free Report) .
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>